Doug Kass

|RSS

Doug Kass is the president of Seabreeze Partners Management Inc.Expand

Until 1996, he was senior portfolio manager at Omega Advisors, a $6 billion investment partnership. Before that he was executive senior vice president and director of institutional equities of First Albany Corporation and JW Charles/CSG. He also was a General Partner of Glickenhaus & Co., and held various positions with Putnam Management and Kidder, Peabody. Kass received his bachelor's from Alfred University, and received a master's of business administration in finance from the University of Pennsylvania's Wharton School in 1972. He co-authored "Citibank: The Ralph Nader Report" with Nader and the Center for the Study of Responsive Law and currently serves as a guest host on CNBC's "Squawk Box."Collapse

By

Doug Kass

 | Feb 11, 2016 | 10:59 AM EST
Possible SEC accounting investigation
By

Doug Kass

 | Feb 11, 2016 | 10:38 AM EST
Intrexon (XON) at $29.99 Sage Therapeutics (SAGE) for $29.09 Portola Pharmaceuticals (PTLA) at $29.29 Otonomy (OTIC), priced at  $13.17 Novovax (NVAX) for $4.53 Nektar Therapies (NKTR) at $11.08 Gilead Sciences, paying $87.25 Cempra (CEMP) for $16.41 Celgene at $101.28 Aerie Pharmaceuticals (AERI), priced at $14.39 Acadia Pharmaceuticals (ACAD) for $17.09 Tetraphase Pharmaceuticals (TTPH) at $4.27
By

Doug Kass

 | Feb 11, 2016 | 10:23 AM EST
Here is my cost basis in today's biotech buys: XON $29.99 SAGE $29.09 PTLA $29.29 OTIC $13.17 NVAX $4.53 NKTR $11.08 GILD $87.25 CEMP $16.41....
By

Doug Kass

 | Feb 11, 2016 | 10:07 AM EST
And I am really happy that we are friends again after my particularly misplaced comments a few weeks ago. Live and learn. As you know I face up to my...
By

Doug Kass

 | Feb 11, 2016 | 9:49 AM EST
Coming up.. I have purchased a diversified group of conservative and very speculative biotech stocks this mroning.
By

Doug Kass

 | Feb 11, 2016 | 9:29 AM EST
Peter Boockvar covers U.S. job claims, China, European banks, a possible Federal Reserve rate cut and more this morning: "Initial U.S. jobless claims…

TBT

By

Doug Kass

 | Feb 11, 2016 | 9:28 AM EST
I bought an oddlot in premarket trading at $24.55. Bidding below $24.75 this morning.
By

Doug Kass

 | Feb 11, 2016 | 9:26 AM EST
Seems we are on similar page on bonds. Just about diff in timing.
By

Doug Kass

 | Feb 11, 2016 | 9:18 AM EST
I appreciate your conviction. But I adapt to changing prices as discussed in the last two opening missives on Tues and Wed. I see an improving reward...
By

Doug Kass

 | Feb 11, 2016 | 8:56 AM EST
I added to the following longs: BAC SPY IWM I established at TLT short. I have a big biotech call coming up shortly.

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.